The following is a sample from a larger document.
This section is for: Key Players and Dynamics
The section is from a Focused Issue Brief on: Assessing Scientific Causation Claims in PFAS Exposure Litigation
The primary research jurisdiction is: United States of America
[Back]
Key Players and Dynamics
The landscape of PFAS exposure litigation involves a complex web of scientists, regulatory agencies, industry players, and advocacy organizations whose positions on causation are shaped by institutional roles, funding relationships, and professional incentives. Understanding these dynamics is essential for evaluating the reliability and positioning of evidence in this field.
Academic Research Centers and Leading Scientists
The academic research driving PFAS causation claims emerges primarily from a small number of institutions with established environmental health programs. The Harvard T.H. Chan School of Public Health has produced some of the most frequently cited epidemiological studies linking PFAS exposure to health outcomes, particularly through the work of researchers like Philippe Grandjean and Elsie Sunderland. Grandjean’s research group has published extensively on PFAS and immune system dysfunction, while Sunderland’s work focuses on exposure pathways and bioaccumulation. Their institutional affiliation at Harvard provides credibility, but their research receives funding from the National Institute of Environmental Health Sciences (NIEHS), which has an explicit mission to identify environmental health hazards. This may create perceived incentives that critics argue could influence research framing or emphasis.
The University of Rhode Island’s STEEP (Sources, Transport, Exposure, and Effects of PFAS) program represents another major academic hub. NIEHS directly funds STEEP with over $45 million in grants specifically to study PFAS effects. This concentrated funding has led some critics to argue that research emphasis may favor continued investigation of potential PFAS harms.
Several European institutions also drive research that influences U.S. litigation. The University of Southern Denmark, where Philippe Grandjean also holds appointments, has produced influential birth cohort studies. European regulatory frameworks often incorporate precautionary principles more explicitly than U.S. frameworks, which may influence how findings are evaluated in regulatory contexts. When European findings are cited in U.S. litigation, this difference in regulatory context is rarely acknowledged.
The Icahn School of Medicine at Mount Sinai contributes biomonitoring expertise through researchers like Miriam Calafat. Their biomonitoring work is methodologically straightforward, but their interpretation of what exposure levels mean for health often aligns with regulatory agencies’ precautionary approaches.
Industry-Affiliated Research and Scientists
The primary manufacturers of PFAS maintain their own research capabilities and fund external research through various mechanisms. These companies have produced substantial internal research over decades, much of which remained proprietary until litigation forced disclosure. When this research contradicts academic findings, it faces automatic credibility challenges due to its source, regardless of methodological quality.
3M’s corporate research division employs toxicologists and epidemiologists who have published peer-reviewed research on PFAS. Their scientists, including researchers like Geary Olsen, often reach different conclusions about causation than academic researchers, typically finding weaker evidence of harm or questioning the biological plausibility of proposed mechanisms. While their industry affiliation creates obvious bias concerns, their access to proprietary exposure data and longer-term internal studies sometimes provides information unavailable to academic researchers.
Industry also funds research indirectly through consulting firms and contract research organizations. Gradient Corporation, ChemRisk, and similar firms employ scientists with strong credentials who conduct research and provide expert testimony defending against causation claims.
These firms are frequently retained to evaluate and, where appropriate, challenge plaintiff causation theories.
Their work often emphasizes scientific limitations in plaintiff causation theories, and critics note that their conclusions frequently align with the positions of their clients.
The American Chemistry Council coordinates industry positions on PFAS regulation and funds research through its Long-Range Research Initiative. ACC-funded research tends to emphasize uncertainty and the need for more data before reaching causal conclusions. While this research sometimes identifies genuine scientific gaps, ACC’s advocacy mission means their interpretation of uncertain evidence consistently favors industry positions.
Regulatory Agencies and Their Internal Dynamics
The Environmental Protection Agency occupies a central but complex role in PFAS causation debates. EPA’s Office of Water has taken increasingly aggressive regulatory stances on PFAS, setting maximum contaminant levels near the limits of detection and characterizing any exposure as potentially harmful. EPA’s Office of Chemical Safety and Pollution Prevention, which evaluates new chemicals, has historically been more cautious about causal claims, requiring stronger evidence before restricting industrial chemicals.
These internal tensions within EPA matter because different offices produce different assessments of the same scientific evidence. Office of Water documents emphasizing PFAS risks carry regulatory authority but reflect a precautionary interpretation of uncertain science. When courts cite these positions in litigation as authoritative statements of scientific consensus, the underlying regulatory logic and evidentiary standards may not be apparent.
The Agency for Toxic Substances and Disease Registry conducts health assessments for contaminated sites and has consistently found evidence for PFAS health effects at lower exposure levels than industry scientists consider plausible. ATSDR’s institutional mission is protecting public health in contaminated communities, which may lead it to adopt protective interpretations of uncertain evidence. Courts frequently cite their toxicological profiles and health consultations in litigation, but their precautionary approach and community-focused mission influence their interpretation of ambiguous data.
NIEHS funds most academic PFAS research and has an explicit mandate to identify environmental health hazards. NIEHS grant priorities emphasize identifying potential health effects and understanding mechanisms of harm.
State environmental agencies increasingly drive PFAS policy and litigation. The Massachusetts Department of Environmental Protection and New Jersey Department of Environmental Protection have set some of the nation’s strictest PFAS standards. These state agencies often face direct political pressure from affected communities and environmental advocates, leading them to adopt more protective stances than federal agencies.
Environmental and Public Health Advocacy Organizations
The Environmental Working Group has emerged as perhaps the most influential advocate for aggressive PFAS regulation and extensive liability. EWG produces reports, maintains databases of contaminated sites, and provides expert witnesses for plaintiff litigation. Their institutional mission is advocating for stronger environmental protections, and their interpretation of PFAS science often emphasizes potential high-risk scenarios while expressing skepticism toward industry-funded research.
Critics argue that some EWG reports characterize preliminary findings assertively and place less emphasis on traditional toxicological frameworks such as dose-response modeling.
The Natural Resources Defense Council provides legal expertise and advocacy supporting PFAS litigation and regulation. NRDC’s scientists, including experts like Erik Olson, regularly testify in support of causation claims and advocate for strict liability approaches that minimize the role of scientific uncertainty. Local community groups affected by PFAS contamination provide compelling personal narratives that influence regulatory and legal proceedings. These groups often partner with academic researchers and advocacy organizations, providing access to affected populations for epidemiological studies.
The Science and Environmental Health Network promotes precautionary approaches to environmental regulation that emphasize preventing harm rather than proving causation. Their advocacy promotes precautionary regulatory approaches that place less emphasis on traditional toxicological thresholds such as dose-response demonstration.
Expert Witnesses and Consulting Scientists
The expert witness market for PFAS litigation has created a specialized subset of scientists whose income depends on providing testimony supporting or opposing causation claims. David Carpenter, a retired SUNY Albany researcher, frequently testifies for plaintiffs in PFAS cases, arguing for causation based on biological plausibility and precautionary principles rather than traditional epidemiological evidence. His academic background provides credibility, though courts and opposing experts have at times scrutinized the basis and scope of his causation opinions.
Toxicologist Linda Birnbaum, former director of NIEHS and the National Toxicology Program, has become a prominent voice supporting broad PFAS health concerns after retiring from federal service. Her former regulatory role provides authority for her positions, and her post-retirement advocacy and consulting work have focused on highlighting PFAS health concerns. Defense experts typically include toxicologists and epidemiologists from consulting firms or industry, along with academic researchers whose work questions causation claims. Their industry connections create automatic credibility challenges, but their scientific criticisms sometimes identify genuine weaknesses in causation claims.
International Regulatory Influences
European regulatory agencies, particularly the European Food Safety Authority and various national agencies, have generally taken more precautionary approaches to PFAS than U.S. agencies. Their risk assessments often find effects at lower doses and express greater confidence in limited epidemiological evidence. The Stockholm Convention on Persistent Organic Pollutants has listed several PFAS chemicals, providing an international regulatory precedent that influences domestic litigation. However, the Convention’s focus on persistence and bioaccumulation rather than specific health effects means its listings do not necessarily reflect causal determinations about health outcomes.
Industry Groups and Legal Dynamics
Beyond individual companies, industry trade associations coordinate research and advocacy positions. The Fluoropolymer Products Association and similar groups fund research specifically designed to counter causation claims and provide alternative interpretations of epidemiological evidence. These organizations also coordinate expert witness strategies and fund research at academic institutions through grants that may not clearly identify their industry connections.
The economics of mass tort litigation create additional dynamics that influence scientific positions. Plaintiff law firms invest substantial resources in developing causation evidence and may fund research or expert development that supports their legal theories. Law firms specializing in environmental litigation often maintain relationships with specific academic researchers and expert witnesses, creating ongoing professional relationships that may influence scientific positions.
Many major participants in this field operate within institutional, financial, or professional structures that may influence how scientific evidence is framed and interpreted.
Academic researchers depend on grants from agencies with environmental protection missions. Industry scientists work for companies facing massive liability. Regulatory agencies face political pressure to protect public health. Expert witnesses earn fees for supporting particular legal positions. Understanding these dynamics does not invalidate any particular finding, but it explains why the same scientific evidence often supports dramatically different conclusions about causation depending on who interprets it.
[Back]